ARK Invest Exits AMD (AMD) Position, Reallocates to Broadcom and Cerebras

Key Highlights

• ARK Invest offloaded 37,977 shares of AMD valued at approximately $18.1 million on Wednesday
• The firm acquired 57,705 Broadcom shares and 69,585 Cerebras Systems shares as semiconductor alternatives
• ARK divested 59,276 Tempus AI shares via ARKK ETF, totaling more than $4 million
• The fund purchased 47,793 Veracyte shares worth $2.1 million distributed between ARKK and ARKG ETFs
• Additional portfolio reductions included Twist Bioscience, Roblox, and Brera Holdings

This week witnessed significant portfolio adjustments at Cathie Wood’s ARK Invest, with the firm divesting millions in tech holdings while establishing fresh positions in biotechnology and semiconductor companies.

The most substantial transaction occurred on Wednesday, when ARK disposed of 37,977 Advanced Micro Devices shares valued at approximately $18.1 million. AMD stock concluded the trading session with a 0.9% decline at $476.67.

Advanced Micro Devices, Inc., AMD

This divestment represents a continuation of an established pattern. Wood has been systematically reducing ARK’s AMD holdings during recent months, despite the stock experiencing gains exceeding 100% year-to-date.

As a semiconductor replacement strategy, ARK acquired 57,705 Broadcom shares alongside 69,585 Cerebras Systems shares during the identical trading session. Broadcom concluded trading with a 4.5% gain at $371.54, while Cerebras advanced 2.5% to reach $186.67.

Notwithstanding these sales, ARK maintains larger AMD holdings compared to either replacement position. The flagship ARK Innovation ETF currently holds $193.3 million in AMD, contrasted with $149.5 million in Cerebras and $95.3 million in Broadcom.

Continued Reduction in Tempus AI Holdings

Thursday witnessed ARK selling an additional 59,276 Tempus AI shares through the ARKK ETF, representing slightly over $4 million. This transaction extends a sequence of Tempus AI reductions executed earlier during the week.

The firm simultaneously divested 22,225 Twist Bioscience shares distributed across ARKK and ARKG ETFs, generating $3.3 million in proceeds. This represents another recurring transaction pattern observed throughout the week.

Additional modest reductions encompassed 1,001 Roblox shares worth $37,597 and 29,385 Brera Holdings shares totaling $116,658.

Increased Investment in Biotechnology Sector

Regarding acquisitions, ARK purchased 47,793 Veracyte shares for $2.1 million, distributed between ARKK and ARKG portfolios. This transaction signals heightened conviction in the oncological diagnostics specialist.

Additionally, ARK acquired 5,085 Scribe Therapeutics shares through the ARKG ETF for $161,194, maintaining its consistent biotechnology investment approach.

These transactions demonstrate ARK’s capital reallocation from select technology holdings toward genomics and biotechnology—sectors that have consistently anchored Wood’s investment philosophy.

Wood established ARK’s prominence through concentrated positions in genomics, robotics, and artificial intelligence sectors, notably including an early Tesla investment. Nevertheless, the flagship ARKK fund has generated approximately -9% annualized returns throughout the previous five-year period.

Current trading activity indicates Wood is executing another strategic repositioning, reducing AMD and Tempus AI exposure while expanding positions in Broadcom, Cerebras, and Veracyte.

ARK’s ARKK ETF advanced 1.87% while the ARKG ETF climbed 0.85% during Thursday’s trading session.

The post ARK Invest Exits AMD (AMD) Position, Reallocates to Broadcom and Cerebras appeared first on Blockonomi.